Khokon Miah Akanda: 2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke
Khokon Miah Akanda, Senior Brand Executive at Apex Pharma Limited, shared on LinkedIn:
“Major Updates in Stroke Care: 2026 AHA/ASA Guidelines Released Today
The American Heart Association and American Stroke Association have released the 2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke. These updates represent significant shifts in prehospital triage, thrombolytic choices, and post-procedural management.
Key Takeaways for Clinicians and Industry Leaders:
• Tenecteplase is Mainstream: The guidelines now endorse Tenecteplase (0.25 mg/kg) as a reasonable alternative to Alteplase for eligible patients within the 4.5-hour window.
• Expanded EVT Eligibility: Endovascular Thrombectomy (EVT) is now strongly recommended for select patients with large ischemic core strokes and basilar artery occlusions.
• Prehospital Triage: New emphasis on direct transport to EVT capable centers for suspected Large Vessel Occlusion (LVO), bypassing smaller centers when appropriate logistics exist.
• Pediatric Care: For the first time, guidelines include specific recommendations for endovascular treatment in children.
Management Shifts
Mild Stroke: Routine IV thrombolysis is not recommended for non-disabling deficits; Dual Antiplatelet Therapy (DAPT) is preferred.
Blood Pressure: Intensive lowering (<140 mm Hg) immediately post-reperfusion is not recommended and may be harmful.
Glycemic Control: Intensive glucose control between (80-130 mg/dL) is advised against due to hypoglycemia risk.
These guidelines push for faster, more precise interventions and open new doors for therapeutic options.”
Stay updated with Hemostasis Today.
-
Mar 6, 2026, 16:51Priya Reehal: Highlighting The Central Role of Nurses in Cardio-Oncology
-
Mar 6, 2026, 16:50Rainer Kaiser: Blinatumomab Shows Remarkable Response in Multi-Refractory ITP and APS
-
Mar 6, 2026, 16:18Laila Shalabi: Clopidogrel, Aspirin, and the Role of PPIs in Coronary Artery Disease
-
Mar 6, 2026, 16:17Paul McKenzie: The Value of Gene Therapy in Bleeding Disorders
-
Mar 6, 2026, 16:15Basma El Homasany: The ‘Little Brain’ of the Heart and Its Role in Health
-
Mar 6, 2026, 16:14Jamal Rana: Family History and Polygenic Risk for Coronary Heart Disease
-
Mar 6, 2026, 15:43Kristy Ainslie: Breaking Down the Discovery and FDA Approval of Drug Carriers
-
Mar 6, 2026, 15:18Claudio Laudani: Efficacy and Safety of Colchicine for Secondary Prevention in Coronary Artery Disease
-
Mar 6, 2026, 15:09Chris Simon: Persona PLUS Receives FDA Clearance for Patent‑Protected Plasma Apheresis